(MENAFN- GetNews)


"Acute Coronary Syndrome Competitive Landscape"Acute Coronary Syndrome companies include Janssen Research & Development, DalCor Pharmaceuticals, Hyloris Pharmaceuticals, and others.

(Albany, USA) DelveInsight's “Acute Coronary Syndrome – Pipeline Insight, 2025” highlights over 5+ active clinical assets targeting diverse mechanisms in ACS, including PCSK9 inhibitors, Factor XIa inhibitors, colchicine-based anti-inflammatories, and agents addressing ischemia-reperfusion injury. Leading developers such as Janssen Research & Development, DalCor Pharmaceuticals, and Hyloris Pharmaceuticals are driving innovations across both acute and post-ACS stages.

The report emphasizes the rise of biomarker-driven trials, precision medicine strategies, and long-term cardiovascular outcome endpoints. As regulators focus on high-risk populations, collaborations are accelerating progress in the field.

A growing understanding of inflammation, residual lipid risk, and platelet biology is steering the ACS pipeline toward long-term cardioprotection rather than just acute stabilization. Despite advances in interventions and dual antiplatelet therapy, ACS remains a significant global burden, sustaining demand for safer and more effective cardioprotective, lipid-lowering, anti-inflammatory, and antithrombotic therapies.

Interested in learning more about the current treatment landscape and the key drivers shaping the Acute Coronary Syndrome pipeline? Click here: Acute Coronary Syndrome Pipeline Outlook

Key Takeaways from the Acute Coronary Syndrome Pipeline Report

• DelveInsight's Acute Coronary Syndrome pipeline analysis depicts a strong space with 5+ active players working to develop 5+ pipeline drugs for Acute Coronary Syndrome treatment.
• The leading Acute Coronary Syndrome companies include Janssen Research & Development, DalCor Pharmaceuticals, Hyloris Pharmaceuticals, and others are evaluating their lead assets to improve the Acute Coronary Syndrome treatment landscape.
• Key Acute Coronary Syndrome pipeline therapies in various stages of development include Milvexian, Dalcetrapib, HY-074, and others.
• In June 2025, a BMJ investigation uncovered serious concerns over data used in ACS trials for ticagrelor (Brilinta), an FDA-approved antiplatelet since 2011, citing inconsistencies in platelet data from two early trials, raising questions about its approval basis.
• In May 2025, the EuroPCR 4D-ACS trial showed that a one-month dual antiplatelet therapy (aspirin + prasugrel) followed by low-dose prasugrel monotherapy significantly reduced bleeding events without increasing ischemic risk post-PCI in ACS patients
• In February 2025, the ACC/AHA/ACEP/NAEMSP/SCAI released updated guidelines for managing acute coronary syndromes (unstable angina, NSTEMI, STEMI), merging previous STEMI and NSTEMI guidance and emphasizing advanced ECG use, serial troponins, and intracoronary imaging

Request a sample and discover the recent breakthroughs happening in the Acute Coronary Syndrome pipeline landscape: Acute Coronary Syndrome Clinical Trials and FDA Approvals

Acute Coronary Syndrome Overview

The treatment landscape for Acute Coronary Syndrome (ACS) is undergoing significant transformation as emerging therapies focus on overcoming limitations of standard antiplatelet and anti-inflammatory drugs. With high unmet clinical needs related to drug resistance, bleeding risk, and long-term cardiovascular event recurrence, pipeline agents are being developed to offer more precise, safer, and faster-acting alternatives. Among the most notable candidates are Vicagrel by Jiangsu Vcare Pharmaceutical Technology and Orticumab by Abcentra, both of which represent innovative approaches to ACS management.

Find out more about Acute Coronary Syndrome medication @ Acute Coronary Syndrome Drugs and Therapies

Acute Coronary Syndrome Drugs Analysis

Vicagrel - Jiangsu Vcare Pharmaceutical Technology Co., Ltd.

Vicagrel is an innovative antiplatelet agent developed through a collaboration between Jiangsu Vcare and China Pharmaceutical University. Holding complete intellectual property rights, Jiangsu Vcare designed Vicagrel to generate the same active metabolite as clopidogrel but through a novel metabolic pathway. This design aims to bypass clopidogrel resistance and reduce adverse drug interactions commonly observed during co-administration. Vicagrel boasts a faster onset of action and requires a lower dose, making it particularly suitable for emergency use while potentially minimizing dose-related side effects. The company has submitted a New Drug Application (NDA) to the U.S. FDA for Vicagrel capsules, targeting thrombotic cardiovascular and cerebrovascular conditions such as ACS, ischemic stroke, and peripheral arterial disease. The drug is currently in the preregistration stage for Acute Coronary Syndrome.

Orticumab - Abcentra

Orticumab is a first-in-class, fully human IgG1 monoclonal antibody being developed by Abcentra to treat inflammation-driven atherosclerotic events in ACS. Unlike systemic anti-inflammatory treatments, Orticumab adopts a highly targeted mechanism by binding to oxidized LDL (oxLDL), specifically the malondialdehyde-modified apolipoprotein B-100 epitope. This localized action is designed to reduce macrophage activation within unstable plaques, thereby lowering the risk of rupture and subsequent acute coronary events. As an inflammation-modulating biologic, Orticumab presents a promising new approach to long-term cardiovascular protection in ACS and is currently in Phase II clinical development.

Learn more about the novel and emerging Acute Coronary Syndrome pipeline therapies at

Acute Coronary Syndrome Therapeutic Analysis

By Product Type

• Mono
• Combination
• Mono/Combination.

By Stage

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Acute Coronary Syndrome Pipeline Report

• Coverage: Global
• Key Acute Coronary Syndrome Companies: Janssen Research & Development, DalCor Pharmaceuticals, Hyloris Pharmaceuticals, and others.
• Key Acute Coronary Syndrome Pipeline Therapies: Milvexian, Dalcetrapib, HY-074, and others.

Dive deep into rich insights for drugs used for Acute Coronary Syndrome treatment, visit: Acute Coronary Syndrome Drugs in Pipeline

Table of Contents

1. Introduction

2. Executive Summary

3. Acute Coronary Syndrome Pipeline: Overview

4. Analytical Perspective In-depth Commercial Assessment

5. Acute Coronary Syndrome Pipeline Therapeutics

6. Acute Coronary Syndrome Pipeline: Late-Stage Products (Phase III)

7. Acute Coronary Syndrome Pipeline: Mid-Stage Products (Phase II)

8. Acute Coronary Syndrome Pipeline: Early Stage Products (Phase I)

9. Therapeutic Assessment

10. Inactive Products

11. Company-University Collaborations (Licensing/Partnering) Analysis

12. Key Companies

13. Key Products

14. Unmet Needs

15. Market Drivers and Barriers

16. Future Perspectives and Conclusion

17. Analyst Views

18. Appendix

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN11112025003238003268ID1110329533